SG11201703403TA - Anti-tim-3 antibodies - Google Patents

Anti-tim-3 antibodies

Info

Publication number
SG11201703403TA
SG11201703403TA SG11201703403TA SG11201703403TA SG11201703403TA SG 11201703403T A SG11201703403T A SG 11201703403TA SG 11201703403T A SG11201703403T A SG 11201703403TA SG 11201703403T A SG11201703403T A SG 11201703403TA SG 11201703403T A SG11201703403T A SG 11201703403TA
Authority
SG
Singapore
Prior art keywords
tim
antibodies
Prior art date
Application number
SG11201703403TA
Inventor
Cheng-I Wang
Hsueh Ling Janice Oh
Siok Ping Yeo
Yun Pei Sharon Goh
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB201419089A priority Critical patent/GB201419089D0/en
Priority to GB201419092A priority patent/GB201419092D0/en
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to PCT/SG2015/050415 priority patent/WO2016068803A1/en
Publication of SG11201703403TA publication Critical patent/SG11201703403TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061Blood cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG11201703403TA 2014-10-27 2015-10-27 Anti-tim-3 antibodies SG11201703403TA (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB201419089A GB201419089D0 (en) 2014-10-27 2014-10-27 Anti-TIM-3 antibodies
GB201419092A GB201419092D0 (en) 2014-10-27 2014-10-27 Anti-TIM-3 antibodies
PCT/SG2015/050415 WO2016068803A1 (en) 2014-10-27 2015-10-27 Anti-tim-3 antibodies

Publications (1)

Publication Number Publication Date
SG11201703403TA true SG11201703403TA (en) 2017-05-30

Family

ID=55857945

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201703403TA SG11201703403TA (en) 2014-10-27 2015-10-27 Anti-tim-3 antibodies
SG10201803042PA SG10201803042PA (en) 2014-10-27 2015-10-27 Anti-tim-3 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201803042PA SG10201803042PA (en) 2014-10-27 2015-10-27 Anti-tim-3 antibodies

Country Status (9)

Country Link
US (2) US10259874B2 (en)
EP (1) EP3212231A4 (en)
JP (1) JP6709215B2 (en)
KR (1) KR20170075778A (en)
CN (2) CN110294807A (en)
AU (1) AU2015340056A1 (en)
CA (1) CA2965960A1 (en)
SG (2) SG11201703403TA (en)
WO (1) WO2016068803A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6709215B2 (en) 2014-10-27 2020-06-10 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ Anti-TIM-3 antibody
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
CN107922484A (en) * 2015-03-06 2018-04-17 索伦托治疗有限公司 With reference to the Antybody therapy agent of TIM3
EP3337826A1 (en) * 2015-08-20 2018-06-27 Sutro Biopharma, Inc. Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
MX2018014387A (en) 2016-05-27 2019-03-14 Agenus Inc Anti-tim-3 antibodies and methods of use thereof.
TW201803905A (en) 2016-06-20 2018-02-01 克馬伯有限公司 Multispecific antibodies for immuno-oncology
BR112019000431A2 (en) 2016-07-14 2019-07-09 Squibb Bristol Myers Co antibodies against tim3 and their uses
MX2019002242A (en) * 2016-08-26 2019-08-16 Beigene Ltd Anti-tim-3 antibodies and use thereof.
CN108264557A (en) * 2016-12-30 2018-07-10 上海欣百诺生物科技有限公司 A kind of combination CD3 and T cell bear bifunctional molecule and its application of costimulatory molecules
WO2018129090A1 (en) * 2017-01-03 2018-07-12 Trellis Bioscience, Llc Native human antibodies for immune checkpoint modulation targets tim-3 and b7-h3
CN111094982A (en) 2017-08-28 2020-05-01 百时美施贵宝公司 TIM-3 antagonists for the treatment and diagnosis of cancer
SG11202004172UA (en) 2017-11-10 2020-06-29 Agency Science Tech & Res Il2rbeta/common gamma chain antibodies
KR20200109339A (en) 2018-01-16 2020-09-22 브리스톨-마이어스 스큅 컴퍼니 How to treat cancer using antibodies to TIM3
WO2019165982A1 (en) * 2018-02-28 2019-09-06 WuXi Biologics Ireland Limited Monoclonal antibody against human lag-3, method for preparing same, and use thereof
CN110272489A (en) * 2018-03-15 2019-09-24 珠海市丽珠单抗生物技术有限公司 A kind of full Humanized antibody molecules for TIM-3, antigen-binding fragment and its medical usage
CN111886023A (en) * 2018-04-24 2020-11-03 安源医药科技(上海)有限公司 Antibodies to TIM-3 and uses thereof
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
WO2020014271A1 (en) * 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses
WO2020094836A1 (en) 2018-11-09 2020-05-14 Euchloe Bio Pte. Ltd. Il2rbeta/common gamma chain antibodies
WO2020097336A1 (en) * 2018-11-09 2020-05-14 Beth Israel Deaconess Medical Center Cdcp1-targeted therapies
WO2020094834A1 (en) 2018-11-09 2020-05-14 Euchloe Bio Pte. Ltd. Il2rbeta/common gamma chain antibodies
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258726A1 (en) 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
ES2192426B1 (en) 2000-05-11 2005-02-16 Universidad De Vigo Sm50 / 20 human monoclonal antibody recognizing human leukocytes, and their use in therapy.
AU2003298816C1 (en) 2002-12-02 2010-12-16 Amgen Fremont, Inc. Antibodies directed to Tumor Necrosis Factor and uses thereof
WO2004084823A2 (en) 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
PT2100618E (en) 2005-06-17 2014-04-07 Philadelphia Health & Educatio An anti-pdgfralpha antibody for use in the treatment of metastatic bone cancer
JP2009515897A (en) 2005-11-10 2009-04-16 キュラジェン コーポレイション Methods of treating ovarian and renal cancer using antibodies to immunoglobulin domains of murine domain and mucin domain 1 (TIM-1) antigen
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
ES2571235T3 (en) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedure for the treatment of a blood tumor that uses the anti-TIM-3 antibody
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
EP3363499A1 (en) * 2010-06-11 2018-08-22 Kyowa Hakko Kirin Co., Ltd. Anti-tim-3 antibody
CA2802344A1 (en) * 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2013006490A2 (en) * 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
CN102392038B (en) 2011-11-01 2013-04-17 浙江大学 Expression vector for deleting exogenous genes in polished rice of transgenic rice and application thereof
CN102492038B (en) * 2011-12-09 2014-05-28 中国人民解放军军事医学科学院基础医学研究所 Anti-human Tim-3 neutralized monoclonal antibody L3D and application thereof
US10513540B2 (en) 2012-07-31 2019-12-24 The Brigham And Women's Hospital, Inc. Modulation of the immune response
US20150284459A1 (en) 2012-10-31 2015-10-08 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
CN103936853B (en) * 2014-01-26 2016-08-17 中国人民解放军军事医学科学院基础医学研究所 A kind of detection TIM-3 test kit and using method thereof
SG11201605627TA (en) 2014-01-31 2016-08-30 Novartis Ag Antibody molecules to tim-3 and uses thereof
JP6709215B2 (en) 2014-10-27 2020-06-10 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ Anti-TIM-3 antibody
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
CN104592388B (en) * 2015-03-02 2017-05-31 中国人民解放军总医院 A kind of antigen-binding portion thereof of the monoclonal antibody of anti-human Tim 3

Also Published As

Publication number Publication date
WO2016068803A1 (en) 2016-05-06
EP3212231A1 (en) 2017-09-06
US20190185564A1 (en) 2019-06-20
EP3212231A4 (en) 2018-03-28
CN110294807A (en) 2019-10-01
JP2017536111A (en) 2017-12-07
SG10201803042PA (en) 2018-06-28
CN107405397B (en) 2020-08-25
JP6709215B2 (en) 2020-06-10
AU2015340056A1 (en) 2017-05-25
CN107405397A (en) 2017-11-28
CA2965960A1 (en) 2016-05-06
US20170240633A1 (en) 2017-08-24
US10259874B2 (en) 2019-04-16
KR20170075778A (en) 2017-07-03

Similar Documents

Publication Publication Date Title
HRP20191704T1 (en) Multispecific antibodies
ZA201704981B (en) Antibodies to tigit
IL250415D0 (en) Anti-pd-l1 antibodies
HK1217861A1 (en) Wifi-coordinated laa-lte
ZA201700551B (en) Anti-pd-1 antibodies
PL3227332T3 (en) Multispecific antibodies
IL250583D0 (en) Anti-tigit antibodies
EP3212231A4 (en) Anti-tim-3 antibodies
LT3221346T (en) Antibodies comprising modified heavy constant regions
IL252004D0 (en) Domain-exchanged antibody
EP3212229A4 (en) Anti-tim-3 antibodies
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201410907D0 (en) No details
IL251963D0 (en) Anti-pd-1 antibodies
GB201411320D0 (en) Antibody construct
GB201601073D0 (en) Antibodies
HK1253507A1 (en) Anti-ror1 antibodies
GB201414823D0 (en) Multispecific antibodies
GB2528557B (en) Soundbar
HUE044950T2 (en) Schienenmesssystem
IL257798D0 (en) Anti-lag-3 antibodies
ZA201900373B (en) Anti-tim-3 antibodies
AU361515S (en) Dishrack
IL259048D0 (en) Anti-ror1 antibodies
GB201411420D0 (en) Antibody constructs